352 related articles for article (PubMed ID: 25882520)
1. Structure-based discovery of small molecule hepsin and HGFA protease inhibitors: Evaluation of potency and selectivity derived from distinct binding pockets.
Franco FM; Jones DE; Harris PK; Han Z; Wildman SA; Jarvis CM; Janetka JW
Bioorg Med Chem; 2015 May; 23(10):2328-43. PubMed ID: 25882520
[TBL] [Abstract][Full Text] [Related]
2. Inhibitors of HGFA, Matriptase, and Hepsin Serine Proteases: A Nonkinase Strategy to Block Cell Signaling in Cancer.
Han Z; Harris PK; Jones DE; Chugani R; Kim T; Agarwal M; Shen W; Wildman SA; Janetka JW
ACS Med Chem Lett; 2014 Nov; 5(11):1219-24. PubMed ID: 25408834
[TBL] [Abstract][Full Text] [Related]
3. Piperidine carbamate peptidomimetic inhibitors of the serine proteases HGFA, matriptase and hepsin.
Damalanka VC; Wildman SA; Janetka JW
Medchemcomm; 2019 Sep; 10(9):1646-1655. PubMed ID: 31803403
[TBL] [Abstract][Full Text] [Related]
4. Discovery of Selective Matriptase and Hepsin Serine Protease Inhibitors: Useful Chemical Tools for Cancer Cell Biology.
Damalanka VC; Han Z; Karmakar P; O'Donoghue AJ; La Greca F; Kim T; Pant SM; Helander J; Klefström J; Craik CS; Janetka JW
J Med Chem; 2019 Jan; 62(2):480-490. PubMed ID: 30571119
[TBL] [Abstract][Full Text] [Related]
5. Conformational lability in serine protease active sites: structures of hepatocyte growth factor activator (HGFA) alone and with the inhibitory domain from HGFA inhibitor-1B.
Shia S; Stamos J; Kirchhofer D; Fan B; Wu J; Corpuz RT; Santell L; Lazarus RA; Eigenbrot C
J Mol Biol; 2005 Mar; 346(5):1335-49. PubMed ID: 15713485
[TBL] [Abstract][Full Text] [Related]
6. Recent progress on inhibitors of the type II transmembrane serine proteases, hepsin, matriptase and matriptase-2.
Damalanka VC; Janetka JW
Future Med Chem; 2019 Apr; 11(7):743-769. PubMed ID: 30945556
[TBL] [Abstract][Full Text] [Related]
7. α-Ketobenzothiazole Serine Protease Inhibitors of Aberrant HGF/c-MET and MSP/RON Kinase Pathway Signaling in Cancer.
Han Z; Harris PK; Karmakar P; Kim T; Owusu BY; Wildman SA; Klampfer L; Janetka JW
ChemMedChem; 2016 Mar; 11(6):585-99. PubMed ID: 26889658
[TBL] [Abstract][Full Text] [Related]
8. Active site mapping of trypsin, thrombin and matriptase-2 by sulfamoyl benzamidines.
Dosa S; Stirnberg M; Lülsdorff V; Häußler D; Maurer E; Gütschow M
Bioorg Med Chem; 2012 Nov; 20(21):6489-505. PubMed ID: 23026080
[TBL] [Abstract][Full Text] [Related]
9. Structure-activity relationship studies of dipeptide-based hepsin inhibitors with Arg bioisosteres.
Kwon H; Ha H; Jeon H; Jang J; Son SH; Lee K; Park SK; Byun Y
Bioorg Chem; 2021 Feb; 107():104521. PubMed ID: 33334587
[TBL] [Abstract][Full Text] [Related]
10. Pericellular activation of hepatocyte growth factor by the transmembrane serine proteases matriptase and hepsin, but not by the membrane-associated protease uPA.
Owen KA; Qiu D; Alves J; Schumacher AM; Kilpatrick LM; Li J; Harris JL; Ellis V
Biochem J; 2010 Feb; 426(2):219-28. PubMed ID: 20015050
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of pro-HGF activation by SRI31215, a novel approach to block oncogenic HGF/MET signaling.
Owusu BY; Bansal N; Venukadasula PK; Ross LJ; Messick TE; Goel S; Galemmo RA; Klampfer L
Oncotarget; 2016 May; 7(20):29492-506. PubMed ID: 27121052
[TBL] [Abstract][Full Text] [Related]
12. Hepatocyte growth factor activation inhibitors (HAI-1 and HAI-2) regulate HGF-induced invasion of human breast cancer cells.
Parr C; Jiang WG
Int J Cancer; 2006 Sep; 119(5):1176-83. PubMed ID: 16557597
[TBL] [Abstract][Full Text] [Related]
13. Hepatocyte growth factor activator (HGFA): molecular structure and interactions with HGFA inhibitor-1 (HAI-1).
Eigenbrot C; Ganesan R; Kirchhofer D
FEBS J; 2010 May; 277(10):2215-22. PubMed ID: 20402765
[TBL] [Abstract][Full Text] [Related]
14. Design and synthesis of novel and potent inhibitors of the type II transmembrane serine protease, matriptase, based upon the sunflower trypsin inhibitor-1.
Li P; Jiang S; Lee SL; Lin CY; Johnson MD; Dickson RB; Michejda CJ; Roller PP
J Med Chem; 2007 Nov; 50(24):5976-83. PubMed ID: 17985858
[TBL] [Abstract][Full Text] [Related]
15. Secondary amides of sulfonylated 3-amidinophenylalanine. New potent and selective inhibitors of matriptase.
Steinmetzer T; Schweinitz A; Stürzebecher A; Dönnecke D; Uhland K; Schuster O; Steinmetzer P; Müller F; Friedrich R; Than ME; Bode W; Stürzebecher J
J Med Chem; 2006 Jul; 49(14):4116-26. PubMed ID: 16821772
[TBL] [Abstract][Full Text] [Related]
16. Identification of the first low-molecular-weight inhibitors of matriptase-2.
Sisay MT; Steinmetzer T; Stirnberg M; Maurer E; Hammami M; Bajorath J; Gütschow M
J Med Chem; 2010 Aug; 53(15):5523-35. PubMed ID: 20684597
[TBL] [Abstract][Full Text] [Related]
17. Structure of catalytic domain of Matriptase in complex with Sunflower trypsin inhibitor-1.
Yuan C; Chen L; Meehan EJ; Daly N; Craik DJ; Huang M; Ngo JC
BMC Struct Biol; 2011 Jun; 11():30. PubMed ID: 21693064
[TBL] [Abstract][Full Text] [Related]
18. Phosphono Bisbenzguanidines as Irreversible Dipeptidomimetic Inhibitors and Activity-Based Probes of Matriptase-2.
Häußler D; Mangold M; Furtmann N; Braune A; Blaut M; Bajorath J; Stirnberg M; Gütschow M
Chemistry; 2016 Jun; 22(25):8525-35. PubMed ID: 27214780
[TBL] [Abstract][Full Text] [Related]
19. Limiting the Number of Potential Binding Modes by Introducing Symmetry into Ligands: Structure-Based Design of Inhibitors for Trypsin-Like Serine Proteases.
Furtmann N; Häußler D; Scheidt T; Stirnberg M; Steinmetzer T; Bajorath J; Gütschow M
Chemistry; 2016 Jan; 22(2):610-25. PubMed ID: 26625703
[TBL] [Abstract][Full Text] [Related]
20. Proteolytic activation of pro-macrophage-stimulating protein by hepsin.
Ganesan R; Kolumam GA; Lin SJ; Xie MH; Santell L; Wu TD; Lazarus RA; Chaudhuri A; Kirchhofer D
Mol Cancer Res; 2011 Sep; 9(9):1175-86. PubMed ID: 21875933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
